{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:25:27Z","timestamp":1786119927049,"version":"build-2736575974"},"reference-count":101,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/ijg.0b013e31821dac2a","type":"journal-article","created":{"date-parts":[[2011,6,15]],"date-time":"2011-06-15T09:01:18Z","timestamp":1308128478000},"page":"433-449","source":"Crossref","is-referenced-by-count":9,"title":["Long-term Medical Management of Primary Open-Angle Glaucoma and Ocular Hypertension in the UK"],"prefix":"10.1097","volume":"21","author":[{"given":"Michelle","family":"Orme","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R6-1-20210208","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial.","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R7-1-20210208","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study. A randomised trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma.","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R8-1-20210208","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2004.04.054","article-title":"Risk assessment in the management of patients with ocular hypertension.","volume":"138","author":"Weinreb","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R11-1-20210208","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/bjo.2005.088666","article-title":"The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003.","volume":"90","author":"Owen","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R13-1-20210208","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1185\/03007990903498786","article-title":"A mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension.","volume":"26","author":"Orme","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R14-1-20210208","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00019053-200624080-00002","article-title":"Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.","volume":"24","author":"Orme","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"R16-1-20210208","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nedt.2005.10.001","article-title":"Trends in the nature of provision in ophthalmology services and resources and barriers to education in ophthalmic nursing: 3rd National UK survey.","volume":"26","author":"Czuber-Dochan","year":"2006","journal-title":"Nurse Edu Today"},{"key":"R20-1-20210208","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","article-title":"Effects on intraocular pressure and side effects of 0.005 latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.","volume":"102","author":"Alm","year":"1995","journal-title":"Ophthalmology"},{"key":"R21-1-20210208","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bjo.79.1.12","article-title":"Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. (see comment).","volume":"79","author":"Alm","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"R22-1-20210208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2005.02.043","article-title":"The safety and efficacy of travoprost 0.004timolol 0.5 fixed combination ophthalmic solution.","volume":"140","author":"Barnebey","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R23-1-20210208","first-page":"729","article-title":"A study of replacement of timolol-pilocarpine with latanoprost in pseudoexfoliation glaucoma.","volume":"27","author":"Bojic","year":"2003","journal-title":"Collegium Antropologicum"},{"key":"R24-1-20210208","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00061198-199902000-00007","article-title":"Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.","volume":"8","author":"Bucci","year":"1999","journal-title":"J Glaucoma"},{"key":"R25-1-20210208","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","article-title":"Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"R26-1-20210208","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.ijg.0000151881.99607.4e","article-title":"United States Latanoprost Brimonidine Study G. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.","volume":"14","author":"Camras","year":"2005","journal-title":"J Glaucoma"},{"key":"R27-1-20210208","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/bjo.2006.094326","article-title":"Intraocular pressure-lowering efficacy of bimatoprost 0.03 and travoprost 0.004 in patients with glaucoma or ocular hypertension.","volume":"90","author":"Cantor","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R28-1-20210208","first-page":"312","article-title":"Prostaglandin analogs and blood-aqueous barrier integrity: a flare cell meter study.","volume":"218","author":"Cellini","year":"2004","journal-title":"Int J Ophthalmol"},{"key":"R29-1-20210208","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/S0161-6420(03)00662-6","article-title":"A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.","volume":"110","author":"Coleman","year":"2003","journal-title":"Ophthalmology"},{"key":"R30-1-20210208","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/112067210501500304","article-title":"Safety and efficacy of bimatoprost 0.03 versus timolol maleate 0.5dorzolamide 2 fixed combination.","volume":"15","author":"Day","year":"2005","journal-title":"Eur J Ophthalmol"},{"key":"R31-1-20210208","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/112067210601600308","article-title":"A comparison of morning and evening instillation of a combination travoprost 0.004timolol 0.5 ophthalmic solution.","volume":"16","author":"Denis","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"R32-1-20210208","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s004170050375","article-title":"The additive intraocular pressure-lowering effect of latanoprost 0.005 daily once and pilocarpine 2 t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.","volume":"238","author":"Diestelhorst","year":"2000","journal-title":"Graef Arch Clin Exp Ophthalmol"},{"key":"R33-1-20210208","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004170050124","article-title":"Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma.","volume":"236","author":"Diestelhorst","year":"1998","journal-title":"Graef Arch Clin Exp Ophthalmol"},{"key":"R34-1-20210208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bjo.2003.018234","article-title":"European Latanoprost Fixed Combination Study G. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.","volume":"88","author":"Diestelhorst","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R35-1-20210208","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ophtha.2005.06.027","article-title":"European Canadian Latanoprost Fixed Combination Study G. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.","volume":"113","author":"Diestelhorst","year":"2006","journal-title":"Ophthalmology"},{"key":"R38-1-20210208","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0149-2918(01)80150-8","article-title":"Brimonidine versus Latanoprost Study G. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.","volume":"23","author":"DuBiner","year":"2001","journal-title":"Clin Ther"},{"key":"R40-1-20210208","first-page":"332","article-title":"Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients.","volume":"220","author":"Erkin","year":"2006","journal-title":"Int J Ophthalmol"},{"key":"R41-1-20210208","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1600-0420.2004.0205.x","article-title":"Groups CvXS. Efficacy and tolerability of the dorzolamide 2timolol 0.5 combination (COSOPT) versus 0.005 (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.","volume":"82","author":"Fechtner","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R42-1-20210208","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0161-6420(02)01010-2","article-title":"Comparison of travoprost 0.0015 and 0.004 with timolol 0.5 in patients with elevated intraocular pressure: A 6-month, masked, multicenter trial.","volume":"131","author":"Fellman","year":"2002","journal-title":"Ophthalmology"},{"key":"R43-1-20210208","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clinthera.2006.03.001","article-title":"A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004 compared with latanoprost 0: 05timolol 0.5 in patients with primary open-angle glaucoma or ocular hypertension.","volume":"28","author":"Franks","year":"2006","journal-title":"Clin Ther"},{"key":"R44-1-20210208","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02850299","article-title":"Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.","volume":"18","author":"Gandolfi","year":"2001","journal-title":"Advances in Therapy"},{"key":"R45-1-20210208","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1185\/030079906X120959","article-title":"Circadian IOP-lowering efficacy of travoprost 0.004 ophthalmic solution compared to latanoprost 0.005.","volume":"22","author":"Garcia-Feijoo","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R46-1-20210208","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/112067210001000302","article-title":"Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.","volume":"10","author":"Garcia-Sanchez","year":"2000","journal-title":"Eur J Ophthalmol"},{"key":"R47-1-20210208","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/bjo.2003.029330","article-title":"A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.","volume":"88","author":"Garcia-Sanchez","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"suppl 1","key":"R48-1-20210208","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0039-6257(02)00310-7","article-title":"The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients.","volume":"47","author":"Hedman","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R49-1-20210208","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One year, randomizing study comparing bimatoprost and timolol in glaucoma and ocular hypertenstion.","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R50-1-20210208","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/archopht.120.7.915","article-title":"Fixed Combination Investigative G. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial.","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R51-1-20210208","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/112067210601600606","article-title":"The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma.","volume":"16","author":"Hollo","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"R53-1-20210208","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1034\/j.1600-0420.2002.800615.x","article-title":"European latanoprost study g. A comparison of the effects on intraocular pressure of latanoprost 0.005 and the fixed combination of dorzolamide 2 and timolol 0.5 in patients with open-angle glaucoma.","volume":"80","author":"Honrubia","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"R54-1-20210208","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.ijg.0000176935.08392.14","article-title":"A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004timolol 0.5 ophthalmic solution compared to travoprost 0.004 ophthalmic solution and timolol 0.5 dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.","volume":"14","author":"Hughes","year":"2005","journal-title":"J Glaucoma"},{"key":"R55-1-20210208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0420.2003.00049.x","article-title":"The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.","volume":"81","author":"Inan","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"R57-1-20210208","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1600-0420.2004.00358.x","article-title":"A comparison of the effects of dorzolamidetimolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients.","volume":"82","author":"Januleviciene","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R58-1-20210208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00061198-200204000-00003","article-title":"European Latanoprost Study G. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.","volume":"11","author":"Kampik","year":"2002","journal-title":"J Glaucoma"},{"key":"R59-1-20210208","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02850153","article-title":"Efficacy of latanoprost and timolol maleate in black and white patients.","volume":"21","author":"Kitnarong","year":"2004","journal-title":"Advance Ther"},{"key":"R60-1-20210208","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1034\/j.1600-0420.1999.770511.x","article-title":"Comparison of 24 hour control with Timoptic 0.5 and Timoptic-XE 0.5 in exfoliation and primary open-angle glaucoma.","volume":"77","author":"Konstas","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"R61-1-20210208","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archopht.123.7.898","article-title":"Twenty-four-hour control with latanoprost-timolol-fixed combination therapy versus latanoprost therapy.","volume":"123","author":"Konstas","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R62-1-20210208","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ophtha.2004.11.032","article-title":"24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.","volume":"112","author":"Konstas","year":"2005","journal-title":"Ophthalmology"},{"key":"R63-1-20210208","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ophtha.2004.08.022","article-title":"Latanoprost 0.005 versus bimatoprost 0.03 in primary open-angle glaucoma patients.","volume":"112","author":"Konstas","year":"2005","journal-title":"Ophthalmology"},{"key":"R64-1-20210208","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/sj.eye.6701446","article-title":"Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005timolol maleate 0.5 and dorzolamide 2timolol maleate 0.5.","volume":"18","author":"Konstas","year":"2004","journal-title":"Eye"},{"key":"R65-1-20210208","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archopht.124.11.1553","article-title":"24-Hour control with a latanoprost-timolol fixed combination vs timolol alone.","volume":"124","author":"Konstas","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"R66-1-20210208","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ophtha.2005.10.053","article-title":"24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma.","volume":"113","author":"Konstas","year":"2006","journal-title":"Ophthalmology"},{"key":"R67-1-20210208","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0002-9394(02)01460-5","article-title":"A comparison of once-daily morning vs evening dosing of concomitant latanoprosttimolol.","volume":"133","author":"Konstas","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R68-1-20210208","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0161-6420(03)00404-4","article-title":"Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005 versus the timolol and dorzolamide fixed combination.","volume":"110","author":"Konstas","year":"2003","journal-title":"Ophthalmology"},{"key":"R69-1-20210208","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archopht.119.7.994","article-title":"Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management.","volume":"119","author":"Laibovitz","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R70-1-20210208","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0161-6420(01)00605-4","article-title":"Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005 or Timolol gel-forming solution 0.5 in Patients with ocular hypertension.","volume":"108","author":"Larsson","year":"2001","journal-title":"Ophthalmology"},{"key":"R71-1-20210208","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00061198-200104000-00007","article-title":"Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005 and Timolol 0.5 in Patients with ocular hypertension.","volume":"10","author":"Larsson","year":"2001","journal-title":"J Glaucoma"},{"key":"R72-1-20210208","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0161-6420(00)00531-5","article-title":"Latanoprost Corneal Effects Study G. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: A double-masked, randomized, one-year study.","volume":"108","author":"Lass","year":"2001","journal-title":"Ophthalmology"},{"key":"R74-1-20210208","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/sj.eye.6702149","article-title":"A 6-month assessment of bimatoprost 0.03 versus timolol maleate 0.5: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients.","volume":"21","author":"Martin","year":"2007","journal-title":"Eye"},{"key":"R75-1-20210208","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1185\/030079906X80215","article-title":"A comparison of the effects of 0.005 latanoprost and fixed combination dorzolamidetimolol on retrobulbar haemodynamics in previously untreated glaucoma patients.","volume":"22","author":"Martinez","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R76-1-20210208","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1185\/030079904125004529","article-title":"Concomitant administration of travoprost and brinzolamide versus fixed latanoprosttimolol combined therapy: three-month comparison of efficacy and safety.","volume":"20","author":"Martinez de la Casa","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R77-1-20210208","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.ijg.0000212240.11219.49","article-title":"Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.","volume":"15","author":"Maruyama","year":"2006","journal-title":"J Glaucoma"},{"key":"R78-1-20210208","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archopht.1996.01100140137004","article-title":"A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.","volume":"114","author":"Mishima","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R79-1-20210208","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R80-1-20210208","first-page":"50","article-title":"Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma.","volume":"16","author":"Niazi","year":"2004","journal-title":"JAMC"},{"key":"R81-1-20210208","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1185\/030079906X148418","article-title":"Comparing bimatoprost and travoprost in black Americans.","volume":"22","author":"Noecker","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R82-1-20210208","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R83-1-20210208","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bjo.84.6.579","article-title":"A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study.","volume":"84","author":"ODonoghue","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R84-1-20210208","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.clinthera.2004.10.009","article-title":"Switching from latanoprost to fixed-combination latanoprost-timolol: a 2I -day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.","volume":"26","author":"Olander","year":"2004","journal-title":"Clin Ther"},{"key":"R85-1-20210208","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9394(01)01257-0","article-title":"Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5.","volume":"132","author":"Orengo-Nania","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R86-1-20210208","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ophtha.2005.10.045","article-title":"Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.","volume":"113","author":"Orzalesi","year":"2006","journal-title":"Ophthalmology"},{"key":"R87-1-20210208","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archopht.121.4.453","article-title":"The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.","volume":"121","author":"Orzalesi","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R88-1-20210208","first-page":"2566","article-title":"Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.","volume":"41","author":"Orzalesi","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R89-1-20210208","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0021-5155(02)00628-7","article-title":"Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma.","volume":"47","author":"Ozdemir","year":"2003","journal-title":"Jpn J Ophthalmol"},{"key":"R90-1-20210208","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1600-0420.2006.00754.x","article-title":"Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.","volume":"85","author":"Ozturk","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"R92-1-20210208","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00061198-200108000-00012","article-title":"Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.","volume":"10","author":"Petounis","year":"2001","journal-title":"J Glaucoma"},{"key":"R94-1-20210208","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1385\/AO:37:1:033","article-title":"Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma: a 24-month study.","volume":"37","author":"Polo","year":"2005","journal-title":"Ann Ophthalmol"},{"key":"R95-1-20210208","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1167\/iovs.05-1253","article-title":"Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.","volume":"47","author":"Quaranta","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R96-1-20210208","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinthera.2006.04.007","article-title":"A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5, brinzolamide 1, and brimonidine tartrate 0.2 as adjunctive therapies to travoprost 0.004 in adults with primary open-angle glaucoma or ocular hypertension.","volume":"28","author":"Reis","year":"2006","journal-title":"Clin Therap"},{"key":"R97-1-20210208","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ajo.2005.02.058","article-title":"Efficacy and safety of a fixed combination of travoprost 0.004timolol 0.5 ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.","volume":"140","author":"Schuman","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R98-1-20210208","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","article-title":"Fixed Combination LatanoprostTimolol Study G. Efficacy and safety of the fixed combinations latanoprosttimolol versus dorzolamidetimolol in patients with elevated intraocular pressure.","volume":"111","author":"Shin","year":"2004","journal-title":"Ophthalmology"},{"key":"R99-1-20210208","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/112067210301300607","article-title":"Peak pressures: crossover study of timolol and latanoprost.","volume":"13","author":"Sihota","year":"2003","journal-title":"Eur J Ophthalmol"},{"key":"R100-1-20210208","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1742-1241.2003.tb10634.x","article-title":"Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma.","volume":"57","author":"Sodhi","year":"2003","journal-title":"Int J Clinical Pract"},{"key":"R101-1-20210208","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0002-9394(00)00902-8","article-title":"The efficacy and safety of latanoprost 0.005 once daily versus brimonidine 0.2 twice daily in open-angle glaucoma or ocular hypertension.","volume":"131","author":"Stewart","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R102-1-20210208","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1034\/j.1600-0420.2003.00065.x","article-title":"Efficacy and safety of timolol maleatelatanoprost fixed combination versus timolol maleate and brimonidine given twice daily.","volume":"81","author":"Stewart","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"R104-1-20210208","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0149-2918(04)90075-6","article-title":"Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.","volume":"26","author":"Susanna","year":"2004","journal-title":"Clin Ther"},{"key":"R105-1-20210208","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1185\/030079906X121020","article-title":"Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension.","volume":"22","author":"Suzuki","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R106-1-20210208","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000097903","article-title":"Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.","volume":"39","author":"Tamer","year":"2007","journal-title":"Ophthalmic Res"},{"key":"R107-1-20210208","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/bjo.84.7.710","article-title":"Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients.","volume":"84","author":"Waldock","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R109-1-20210208","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0161-6420(96)30750-1","article-title":"A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.","volume":"103","author":"Watson","year":"1996","journal-title":"Ophthalmology"},{"key":"R110-1-20210208","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/archopht.1993.01090100059027","article-title":"The effects on aqueous dynamics of PhXA41, a new prostaglandin F(2alpha) analogue, after topical application in normal and ocular hypertensive human eyes.","volume":"111","author":"Ziai","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"R112-1-20210208","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1167\/iovs.07-0290","article-title":"Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).","volume":"48","author":"Friedman","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R114-1-20210208","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/10807680260362687","article-title":"Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study.","volume":"18","author":"Taylor","year":"2002","journal-title":"J Ocul Pharmacol Ther"},{"key":"R116-1-20210208","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0161-6420(98)92665-3","article-title":"Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study.","volume":"105","author":"Bonomi","year":"1998","journal-title":"Ophthalmology"},{"key":"R117-1-20210208","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1755-3768.1991.tb04839.x","article-title":"Frequency distribution of IOP. Analysis of a material using the gamma distribution.","volume":"69","author":"Davanger","year":"1991","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R118-1-20210208","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ophtha.2006.08.031","article-title":"Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension.","volume":"114","author":"Gordon","year":"2007","journal-title":"Ophthalmology"},{"key":"R119-1-20210208","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ophtha.2006.07.060","article-title":"Fluctuation of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial.","volume":"114","author":"Bengtsson","year":"2007","journal-title":"Ophthalmology"},{"key":"R120-1-20210208","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","article-title":"Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study.","volume":"111","author":"Nouri-Mahdavi","year":"2004","journal-title":"Ophthalmology"},{"key":"R124-1-20210208","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0161-6420(03)00254-9","article-title":"Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states.","volume":"110","author":"Brown","year":"2003","journal-title":"Ophthalmology"},{"key":"R125-1-20210208","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11136-006-9126-8","article-title":"Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity.","volume":"16","author":"Bansback","year":"2007","journal-title":"Qual Life Res"},{"key":"R130-1-20210208","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1185\/030079907X178720","article-title":"A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.","volume":"23","author":"Denis","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R131-1-20210208","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.clinthera.2008.04.006","article-title":"Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure.","volume":"30","author":"Cheng","year":"2008","journal-title":"Clin Ther"},{"key":"R132-1-20210208","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/IJG.0b013e3181666557","article-title":"Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.","volume":"17","author":"Aptel","year":"2008","journal-title":"J Glaucoma"},{"key":"R133-1-20210208","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.icu.0000156139.05323.26","article-title":"Compliance and persistency in glaucoma follow-up treatment.","volume":"16","author":"Schwartz","year":"2005","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Journal of Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00061198-201209000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:30:39Z","timestamp":1786044639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00061198-201209000-00001"}},"subtitle":["Optimizing Cost-Effectiveness and Clinic Resources by Minimizing Therapy Switches"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ijg.0b013e31821dac2a","relation":{},"ISSN":["1057-0829"],"issn-type":[{"value":"1057-0829","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}